Literature DB >> 31075356

A review on the pathophysiology of asthma remission.

Orestes A Carpaij1, Janette K Burgess2, Huib A M Kerstjens3, Martijn C Nawijn2, Maarten van den Berge3.   

Abstract

Asthma is a chronic respiratory condition, which is highly prevalent worldwide. Although no cure is currently available, it is well recognized that some asthma patients can spontaneously enter remission of the disease later in life. Asthma remission is characterized by absence of symptoms and lack of asthma-medication use. Subjects in asthma remission can be divided into two groups: those in clinical remission and those in complete remission. In clinical asthma remission, subjects still have a degree of lung functional impairment or bronchial hyperresponsiveness, while in complete asthma remission, these features are no longer present. Over longer periods, the latter group is less likely to relapse. This remission group is of great scientific interest due to the higher potential to find biomarkers or biological pathways that elicit or are associated with asthma remission. Despite the fact that the definition of asthma remission varies between studies, some factors are reproducibly observed to be associated with remitted asthma. Among these are lower levels of inflammatory markers, which are lowest in complete remission. Additionally, in both groups some degree of airway remodeling is present. Still, the pathological disease state of asthma remission has been poorly investigated. Future research should focus on at least two aspects: further characterisation of the small airways and airway walls in order to determine histologically true remission, and more thorough biological pathway analyses to explore triggers that elicit this phenomenon. Ultimately, this will result in pharmacological targets that provide the potential to steer the course of asthma towards remission.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Airway remodeling; Biomarkers; Clinical asthma remission; Complete asthma remission; Predictors; Prevalence

Mesh:

Substances:

Year:  2019        PMID: 31075356     DOI: 10.1016/j.pharmthera.2019.05.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  11 in total

1.  Age-Dependent Reduction in Asthmatic Pathology through Reprogramming of Postviral Inflammatory Responses.

Authors:  Guy Hazan; Anna Eubanks; Carrie Gierasch; Jeffrey Atkinson; Carolyn Fox; Ariel Hernandez-Leyva; Anne L Rosen; Andrew L Kau; Eugene Agapov; Jennifer Alexander-Brett; Deborah Steinberg; Diane Kelley; Michael White; Derek Byers; Kangyun Wu; Shamus P Keeler; Yong Zhang; Jeffrey R Koenitzer; Elise Eiden; Neil Anderson; Michael J Holtzman; Jeffrey Haspel
Journal:  J Immunol       Date:  2022-02-16       Impact factor: 5.422

2.  Inflammatory Remission in T2 Severe Asthma.

Authors:  Manuel J Rial; Javier Domínguez-Ortega
Journal:  Front Allergy       Date:  2022-05-30

3.  Effect of the COVID-19 Lockdown on Asthma Biological Rhythms.

Authors:  Guy Hazan; Carolyn Fox; Elise Eiden; Neil Anderson; Michael Friger; Jeffrey Haspel
Journal:  J Biol Rhythms       Date:  2022-03-23       Impact factor: 3.649

4.  Asthma Remission Disparities Among US Youth by Sexual Identity and Race/Ethnicity, 2009-2017.

Authors:  Caleb W Curry; Dylan Felt; Kristin Kan; Megan Ruprecht; Xinzi Wang; Gregory Phillips; Lauren B Beach
Journal:  J Allergy Clin Immunol Pract       Date:  2021-05-05

5.  Genetic deletion of the Tas2r143/Tas2r135/Tas2r126 cluster reveals that TAS2Rs may not mediate bitter tastant-induced bronchodilation.

Authors:  Ping Lu; Mai K ElMallah; Zeyu Liu; Chan Wu; Jun Chen; Lawrence M Lifshitz; Ronghua ZhuGe
Journal:  J Cell Physiol       Date:  2021-02-08       Impact factor: 6.513

6.  Assessing small airways dysfunction in asthma, asthma remission and healthy controls using particles in exhaled air.

Authors:  Orestes A Carpaij; Susan Muiser; Alex J Bell; Huib A M Kerstjens; Craig J Galban; Aleksa B Fortuna; Salman Siddiqui; Anna-Carin Olin; Martijn C Nawijn; Maarten van den Berge
Journal:  ERJ Open Res       Date:  2019-10-21

7.  ZDHXB-101 (3',5-Diallyl-2, 4'-dihydroxy-[1,1'-biphen-yl]-3,5'-dicarbaldehyde) protects against airway remodeling and hyperresponsiveness via inhibiting both the activation of the mitogen-activated protein kinase and the signal transducer and activator of transcription-3 signaling pathways.

Authors:  Jun-Xia Jiang; Hui-Juan Shen; Yan Guan; Yong-Liang Jia; Jian Shen; Qi Liu; Qiang-Min Xie; Xiao-Feng Yan
Journal:  Respir Res       Date:  2020-01-13

8.  Epigenome-wide association study identifies DNA methylation markers for asthma remission in whole blood and nasal epithelium.

Authors:  Cancan Qi; Judith M Vonk; Diana A van der Plaat; Maartje A E Nieuwenhuis; F Nicole Dijk; Dylan Aïssi; Valérie Siroux; H Marike Boezen; Cheng-Jian Xu; Gerard H Koppelman
Journal:  Clin Transl Allergy       Date:  2020-12-11       Impact factor: 5.871

9.  Fucoxanthin Ameliorates Oxidative Stress and Airway Inflammation in Tracheal Epithelial Cells and Asthmatic Mice.

Authors:  Shu-Ju Wu; Chian-Jiun Liou; Ya-Ling Chen; Shu-Chen Cheng; Wen-Chung Huang
Journal:  Cells       Date:  2021-05-25       Impact factor: 6.600

10.  Interleukin 4 gene polymorphism (-589C/T) and the risk of asthma: a meta-analysis and met-regression based on 55 studies.

Authors:  Ahmad Kousha; Armita Mahdavi Gorabi; Mehdi Forouzesh; Mojgan Hosseini; Markov Alexander; Danyal Imani; Bahman Razi; Mohammad Javad Mousavi; Saeed Aslani; Haleh Mikaeili
Journal:  BMC Immunol       Date:  2020-10-21       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.